← feed

Is NCT03304964 results overdue?

Yes — results are overdue. Primary completion was 2018-06-01; the FDAAA-801 reporting deadline (2019-06-01) passed 2623 days ago and no results are posted on ClinicalTrials.gov.

A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects

NCT IDNCT03304964 ↗
SponsorForesee Pharmaceuticals Co., Ltd. (INDUSTRY)
PhasePHASE1
StatusCOMPLETED
Primary completion2018-06-01 (ACTUAL)
Reporting deadline2019-06-01 (completion + 365d)
Days overdue2623
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 def80e3371ab9f4b… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03304964. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →